Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two medications used in anesthesia practice:\n\n**Dexmedetomidine** is a highly selective α2-adrenergic receptor agonist that provides sedation, anxiolysis, and analgesia without causing respiratory depression. It works by decreasing activity of noradrenergic neurons in the locus ceruleus, increasing inhibitory GABA neuron activity.\n\n**Rocuronium** is an aminosteroid non-depolarizing neuromuscular blocking agent used to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.\n\nStudies have shown that dexmedetomidine can influence the effects of rocuronium by potentially enhancing neuromuscular blockade. Research indicates that dexmedetomidine may increase plasma rocuronium concentration and decrease the first response (T1) in train-of-four monitoring, suggesting it may alter rocuronium's pharmacokinetics through vasoconstriction. Additionally, dexmedetomidine has been found to reduce pain associated with rocuronium injection and may shorten the onset time of rocuronium-induced neuromuscular blockade.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine + rocuronium.